Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Kailera Therapeutics, Inc. (KLRA) Market Cap & Valuation Ratios

Kailera Therapeutics, Inc. (KLRA) has a market cap of $1.7B, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · read by EquiReason

KLRAKailera Therapeutics, Inc.Follow KLRA — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.7B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
KLRA1.7———————
ZBIO1.8———-12.9%-93%—-137%
MAZE1.7———-6.2%——-50%
URGN1.7—9.4—-9.4%+100%-35%—
STOK1.6—48.0—-11.2%-86%—-95%
NUVB1.6—7.0—-8.0%+1084%-81%-65%
NVAX1.6—2.8—-2.7%-62%-57%—
IMCR1.6—2.6—-2.6%+21%-5%-7%
ABSI1.6—880.5—-6.9%-62%—-92%
TRAX1.6———————
NTLA1.6—19.0——+13%—-68%
Median of these 10—9.4—-7.5%-25%-46%-68%

.

Growth vs. price

each dot a company · hover or tap for values

Kailera Therapeutics, Inc. — questions

What is Kailera Therapeutics, Inc.'s market cap?
$1.7B.

Every figure on this page comes from Kailera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.